NMPA Releases Updated Guidelines for Medical Device Distribution Inspections

Last year, the Guidelines for On-site Inspection of Medical Device Distribution Quality Management Practices issued by the National Medical Products Administration (NMPA) officially came into effect, replacing the 2015 version issued by the former China Food and Drug Administration (CFDA) under document number CFDA Medical Device Supervision [2015] No. 239. These updated Guidelines unify inspection standards and procedures for medical device distribution enterprises across China and serve as a critical compliance reference for overseas manufacturers seeking market access, with clarified requirements for licensing, traceability, and operational quality control.

Background of the Guidelines

In recent years, China’s medical device market has continued to expand, with new products and technologies emerging rapidly. To ensure public safety, the NMPA has strengthened the development of medical device quality management systems. The newly revised Medical Device Distribution Quality Management Practices, effective July 1, 2024, further enhances quality management requirements for medical device distribution. To ensure effective implementation, the NMPA formulated these Guidelines to unify on-site inspection standards and improve regulatory scientificity and effectiveness.

Key Content of the Guidelines

Scope of Application
The Guidelines apply to medical device distribution enterprises undergoing on-site inspections for business licensing (including modifications and renewals), post-filing inspections, and other regulatory inspections. They cover the entire lifecycle of medical device distribution enterprises, ensuring clear inspection criteria from market entry to daily operations.
On-site Inspection Criteria1. Business Licensing Inspections:
- Passed: All applicable requirements are met, or non-conformities are rectified on-site.
- Rectification Required: Key items (marked with “※”) with ≤10% non-conformities and general items (unmarked) with ≤20% non-conformities.
- Failed: Key items with >10% non-conformities or general items with >20% non-conformities.
- Enterprises receiving “Rectification Required” must submit a rectification report within 30 working days. Failure to submit or unsuccessful rectification will result in denial of licensing.

2. Other Inspections (e.g., routine or post-filing inspections):

- Passed: All applicable requirements are met, or non-conformities are rectified on-site.
- Rectification Required: Non-conformities that cannot be resolved on-site.
- Violations of regulations will be handled according to law.

Handling of Reasonable Omissions: Enterprises may identify reasonable omissions based on their business model, scope, or product characteristics, with written justifications subject to confirmation by inspectors. This reflects regulatory flexibility and scientificity, accommodating diverse enterprise scenarios.
Inspection Content and Key PointsThe Guidelines outline eight inspection areas with key points, including:
- Quality Management System Establishment and Improvement: Evaluates whether a comprehensive quality management system exists, including regular internal audits, management reviews, and improvements.
- Roles and Responsibilities: Assesses organizational structure, personnel responsibilities, and operational procedures.
- Personnel and Training: Verifies adequate qualified staff and training/assessment programs.
- Facilities and Equipment: Ensures premises and equipment meet requirements and are maintained/calibrated.
- Procurement, Receiving, and Inspection: Checks legal procurement channels, documentation completeness, and compliance in receiving/inspection.
- Storage and Inventory Management: Reviews standardized warehousing, storage conditions, and regular inventory checks.
- Sales, Distribution, and Transportation: Confirms legal sales channels, complete records, and compliance in distribution/transport.
- After-sales Service: Evaluates after-sales systems and timely response to customer feedback.
Updates in the 2024 Guidelines vs. 2015 Version
1. Expanded Structure:
  - Added a standalone chapter on “Quality Management System Establishment and Improvement,” requiring risk management tools (e.g., FMEA) and encouraging digital/green initiatives.
  - Increased clauses from 66 to 116, with detailed role delineation (e.g., expanding “Quality Personnel Duties” into 12 specific tasks, adding traceability and carrier audits).
2. Enhanced New Business Model Oversight:
  - Clarified requirements for automated retail devices (e.g., license display, environmental monitoring, after-sales mechanisms).
  - Permitted multi-warehouse coordination via third-party logistics, requiring real-time data interoperability.
3. Extended Record Retention and Traceability:
  - Implantable device records: “Permanent retention” (previously “long-term”).
  - Non-implantable records without expiry: Extended from 3 to 5 years.
  - Mandated Unique Device Identification (UDI) integration with sales records.
4. Optimized Inspection Criteria:
  - Key item non-conformity threshold raised from 0% to ≤10%, general item tolerance to ≤20%.
  - Introduced “reasonable omissions” mechanism.
5. Legal Liability and Rectification:
  - Extended rectification period from 20 to 30 working days.
  - Direct linkage to Article 86 of the Medical Device Supervision and Administration Regulation, allowing license revocation for safety violations.

Impacts and Recommendations for Overseas Manufacturers

Overseas manufacturers should conduct self-assessments per the Guidelines, strengthen quality control systems, and enhance oversight in supplier management, procurement, warehousing, logistics, sales, and after-sales services to ensure product safety and traceability.

Further Information

To read the original NMPA announcement about the guidelines for on-site inspection of medical device distribution, please click here.

In accordance with China’s GSP and audit guidelines, Cisema provides customized distributor audit services for manufacturers to ensure their distributors’ quality management systems meet regulatory standards.

If you are a medical device manufacturer with questions about how the 2024 NMPA inspection guidelines affect your compliance strategy for the China market, please contact Cisema.